VICTOR: Post-treatment stage of a Phase III, randomised, double blind, placebo-controlled study of rofecoxib (VIOXX®) in colorectal cancer patients following potentially curative therapy.
Publication: Journal of Clinical Oncology, Volume 28 Issue 30 October 2010

